In FebruaryCephalon exercised its option to acquire Ception Therapeutics, following receipt of positive data from a clinical study in adults with eosinophilic asthma.
Entering into a joint venture operation with Cephalon alone would not have increased their revenue enough to achieve their goals. As the most important patents of Cephalon are about to expire in the short term, a promising pipeline is not enough to comfort the shareholders as the risk of failure is too high.
Such statements are made based upon management's current expectations and beliefs concerning future events and their potential effects on the company and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements.
The transaction reinforces Teva's long term strategy of building out its branded and specialty pharmaceuticals business through diversification and expansion of the company's product portfolio and pipeline. Private Securities Litigation Reform Act of This release contains forward-looking statements, which express the current beliefs and expectations of management.
In addition to positive financial market reactions, both Teva and Cephalon achieved their objectives. It will capture value by providing customers with a broad spectrum of specialty branded products.
Teva's Safe Harbor Statement under the U. Background[ edit ] The company's early research efforts were focused on the development of IGF-1an insulin-like growth factorunder a collaboration with Chiron Corporation to treat amyotrophic lateral sclerosisor Lou Gehrig's Disease, but the product has never been approved.